Antisecretory treatment: clear-cut benefit and potential risk

Proton pump inhibitors (PPI) remain a key element in the management of acid-dependent diseases. The antisecretory drug administration schedule should take into account the nature of the disease and the research data reflected in relevant international consensus. The patient’s adherence to the PPI intake has a significant impact on the results of management of acid-dependent diseases. The benefit of PPI intake significantly exceeds the potential harm that is low or very low. To date, there is no conclusive evidence of the adverse effects of the prolonged use of PPI, however, if there is no indication for the PPI intake, it is not recommended to use high doses of the drug. The pharmacodynamic effect of different PPIs doesn’t differ significantly, however, according to experts’ opinion based on meta-analysis, esomeprazole has some advantage over other drugs.

1. Kheloufi F, Frankel D, Kaspi E et al. Chronic use of proton pump inhibitors, adverse events and potential biological mechanisms: A translational analysis. Therapie, 2017, Oct 14, pii: S0040-5957(17)30155-5. doi: 10.1016/j.therap.2017.08.003.

2. Pimanov SI, Makarenko EV, Dikareva E.A. Antisecretory therapy: from discussions to consensus. Medical News, 2014, 11: 47-52

3. Maev IV, Goncharenko A.Yu., Dicheva D.T. et al. Treatment of ulcerative bleeding and prevention of their relapse: the view of the therapist. Medical Council, 2013, 10: 22-26.

4. Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology, 2017, 152(4): 706–715.

5. Pimanov SI. Proton pump inhibitors in the treatment of ulcer bleeding: metaanalyzes review. Spravochnik Poliklinicheskogo Vracha, 2007, 13: 51-56.

6. Pimanov SI, Makarenko EV. Diagnosis and management of Helicobacter pylori infection: the Maastricht V/ Florence consensus report and comments: a guide for physicians. Minsk: Chetyre Chetverti, 2017. 90 p.

7. Pimanov SI, Makarenko EV. Optimized eradication protocols: guidelines of the American Association of Gastroenterologists. Maastricht V - Florence and Toronto consensus. Medicinskij Sovet, 2017, 15: 10-17.

8. Pimanov SI, Silivonchik NN. Functional gastrointestinal disorders: Rome IV consensus: a guide for physicians. Vitebsk: VSMU, 2016. 190 p.

9. Pimanov SI, Semenova EV, Makarenko EV, Ruselik EA. Gastroduodenal ulcers caused by antiaggregant and non-steroidal anti-inflammatory drugs: prevention according to new guidelines. Consilium medicum. Prilozhenie. Gastroenterology. 2009, 8: 13-20.

10. Pimanov SI, Makarenko EV, Ruselik EA. Prevention of adverse effects of non-steroidal anti-inflammatory drugs: the rules of choice. Medicinskij Sovet, 2012, 9: 68-71.

11. Pimanov SI, Dikareva EA, Makarenko EV. How to reduce gastrointestinal risk when using non-steroidal anti-inflammatory drugs. Consilium medicum, 2014, 2: 95-99.

12. Pimanov SI, Makarenko EV, Dikareva EA. Compliance with proton pump inhibitor co-therapy in chronic usage of nonsteroidal anti-inflammatory drugs. Terapevt. Arkhiv, 2015, 4: 58-61.

13. Katz PO, Gerson LB, Vela MF. Guidelines for the Diagnosis and Management of Gastroeso phageal Reflux Disease. Am. J. Gastroenterol., 2013, 108: 308–328.

14. Pimanov S.I. Treatment of gastroesophageal reflux disease: a brief overview of the recommendations of the American Gastroenterology Association. Part I. Medical Council, 2013, 4: 36-41.

15. Gorgun YuV, Marakhovsky YuK, Pimanov SI. Diagnosis and management of pati ents with diseases of the digestive system: a clinical protocol. Minsk: Professional publications, 2016. 214 p.

16. Pimanov SI, Makarenko EV, Semenova EV, Koroleva YuI. The international consensus guidelines on prevention of gastric cancer and recurrence of gastroduodenal ulcers. Consilium medicum, 2008, 8: 9-15.

17. Cheung KS, Chan EW, Wong AYS et al. Longterm proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut, 2018, 67(1): 28–35.